Cosmos Health Inc (COSM)

Cosmos Health reported record Q3 2025 results with increased revenue, gross profit, and gross margin. The company regained compliance with Nasdaq's minimum bid price requirement. Cosmos Health expanded its Ethereum holdings and launched a strategic partnership with Prime Ledger. CEO Greg Siokas increased his stake in the company throughout 2025. Cosmos Health entered into a manufacturing agreement with Libytec for PathMuscle Medicine. The company commenced U.S. operations with the launch of its Sky Premium Life food supplements brand. A nanotechnology R&D program was announced. The stock price decreased by 41.26% over the past year, with a 10% decline between January 13, 2025, and January 9, 2026.

While specific data on the demand seasonality for Cosmos Health's individual products and services is not explicitly available, the company's diversified portfolio is designed to mitigate the impact of demand fluctuations. Stock price seasonality analysis indicates that May has the highest probability of positive returns, while January may not be an ideal month for stock investment.

Cosmos Health, Inc. is a global healthcare company specializing in the wholesale of pharmaceutical products across Europe, with a diversified and vertically integrated structure, operating within the Health Care sector. It owns a portfolio of proprietary pharmaceutical and nutraceutical brands and manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices through its subsidiary, Cana Laboratories S.A. The company distributes branded generics and OTC medications and is involved in R&D for novel products and telehealth services through the acquisition of ZipDoctor, Inc.

Cosmos Health, Inc. has a growing international presence with operations and expansion efforts across Europe, Asia, and North America. The company maintains offices and distribution centers in Thessaloniki and Athens, Greece, and Harlow, UK. It has a network of over 160 clients and vendors in various countries and commenced U.S. operations in September 2025 with the launch of its Sky Premium Life food supplements brand, utilizing local manufacturing facilities.

Cosmos Health's brand reputation over the past year appears to be generally positive, driven by strategic initiatives and operational improvements, with a news sentiment score of 1.19. The company's rebranding to "Cosmos Health" in July 2022 was intended to better reflect its evolution. Recent news highlights the company's strategic shift towards a diversified, vertically integrated platform and the commencement of U.S. operations with local manufacturing.

Cosmos Health, Inc. has a mix of institutional and individual owners, with institutional investors holding 3.48% of the stock. Major institutional shareholders include BlackRock, Inc., Vanguard Group Inc, Citadel Advisors Llc, Geode Capital Management, Llc, Armistice Capital LLC, XTX Topco Ltd, State Street Corp, Renaissance Technologies Llc, Northern Trust Corp, Susquehanna International Group, Llp, and StoneX Group Inc. Key individual owners and insiders include Grigorios Siokas, Georgios Terzis, Andreas Bovopoulos, Nikolaos Bardakis, and Anastasios Aslidis, with insiders holding 22.20% of the company's stock.